February 11, 2020

NINDS Epilepsy Benchmarks

These articles review the NINDS Epilepsy Benchmarks, examining progress made in epilepsy research and identifying priorities for the next phases of research. This is a process that continues to evolve to reflect scientific advances and community research priorities over time.

  • The Benchmarks: Progress and Emerging Priorities in Epilepsy Research Learn more
  • Epilepsy Benchmarks Area I: Understanding the Causes of Epilepsies and Epilepsy-Related Neurologic, Psychiatric and Somatic Conditions Learn more
  • Epilepsy Benchmarks Area II: Prevent Epilepsy and Its Progression Learn more
  • Epilepsy Benchmarks Area III: Improved Treatment Options for Controlling Seizures and Epilepsy-Related Conditions without Side Effects Learn more
  • Epilepsy Benchmarks Area IV: Limit or Prevent Adverse Consequences of Seizures and Their Treatment Across the Life Span Learn more

Related News

April 15, 2024

Transcriptomic Alterations in Cortical Astrocytes Following the Development of Post-Traumatic Epilepsy (PTE)

Featuring work of CURE Grantees Michelle Olsen and Michelle Theus. This work supports the ideas that astrocytes play a vital role in the progression of epileptogenesis following TBI.

April 15, 2024

Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients

“With such a clear response, we have advanced our planning of the focal epilepsy efficacy study for PRAX-628, expected to begin in the second half of 2024. We extend our thanks to the patients who participated in this PPR study,”

April 15, 2024

Study Reveals Key Mechanisms of a Rare Form of Epilepsy

This study reveals that the presence of KCNQ2 G256W variants affects both molecular and cellular aspects of KCNQ channel activity, including their ion-carrying capacity, expression, and placement within cells.